Among competitors one swimmer had vast experience, Thomas Heilman, 17, swam in the Olympics last summer and broke Michael ...

The new mens range debuted at a VIP fashion show in Palm Beach last week, and will arrive in stores in February for the ...

Lilly Pulitzer is dipping a pastel-painted toe into the world of menswear. After more than six decades of treating its ...

Elevate your golf game with this Lilly Pulitzer matching set, featuring a UPF 50 jacket and skort in a fun pink gingham print for effortless style on the course. Add a touch of coastal charm to ...

Eli Lilly reported third-quarter results before the market opened on Wednesday. Management missed Wall Street estimates and lowered earnings guidance for 2024. Sales of Zepbound and Mounjaro ...

Eli Lilly and Company reported third quarter results and missed expectations and had to lower its guidance, which was a huge disappointment for investors. But in the last few years, Eli Lilly was ...

Drug maker Eli Lilly’s share price plunged Wednesday morning after the company reported worse third-quarter results than expected, especially in its weight-loss drug division, registering a rare ...

Eli Lilly (NYSE:LLY) shares fell ~9% in the premarket on Wednesday, sending ADRs of its rival Novo Nordisk (NVO) lower after the U.S. drugmaker missed Street forecasts with its Q3 2024 financials ...

Eli Lilly has dropped (PDF) the lead candidate from its $2.4 billion takeover of Dice Therapeutics, shifting the focus of its oral IL-17 psoriasis program to a follow-up molecule. Lilly kicked DC ...

Of Lilly’s $3.11 billion in quarterly sales from Mounjaro, $2.4 billion came from the U.S. Related Compounders sue FDA for removing Eli Lilly's tirzepatide from shortage list ...

Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of revenue in Q3 2023 from the sale of rights for the olanzapine portfolio ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Weight-loss drugmaker Eli Lilly delivered lower sales and earnings per share than expected in the third ...